GLOBAL CANINE INFLUENZA VACCINE MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)
Global Canine Influenza Vaccine Market, By Vaccine Type (Recombinant Vaccines, Inactivated Vaccines, and Others), By Virus Type (H3N8 virus and H3N2 virus), By Distribution Channel (Public and Private), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)
In September 2022, Merck Animal Health, a part of Merck & Co., Inc., a pharmaceutical company, announced the launch of the first oral Bordetella bronchisepticaand canine parainfluenza virus vaccine with mucosal protection and easy oral administration. The vaccine has been shown to be effective for the vaccination of healthy dogs aged 7 weeks or older against canine parainfluenza virus and Bordetella bronchiseptica.
In June 2021, Elanco, a U.S.-based pharmaceutical company, and Kindred Biosciences, Inc., a commercial-stage biopharmaceutical company, announced that the parties had entered a definitive agreement for Elanco to acquire KindredBio, a biopharmaceutical company focused on developing novel pet therapeutics based on validated human targets.
Global Canine Influenza Vaccine Market Report Snapshots